Morgan Stanley
ENSC icon

Morgan Stanley’s Ensysce Biosciences ENSC Stock Holding History

Morgan Stanley’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-378
Closed -$843 – 8219
2025
Q2 		$843 Buy
+378
New +$866 ﹤0.01% 7350
2025
Q1 		– Sell
-52
Closed -$423 – 8122
2024
Q4 		$423 Buy
+52
New +$358 ﹤0.01% 7358
2023
Q1 		– Sell
-2
Closed -$207 – 7749
2022
Q4 		$207 Buy
+2
New +$950 ﹤0.01% 7642
2022
Q3 		– Hold
0
– – – 7741
2022
Q2 		– Hold
0
– – – 7846
2022
Q1 		– Hold
0
– – – 7998
2021
Q4 		– Sell
-1
Closed -$9.42K – 7859
2021
Q3 		$10K Buy
+1
New +$19.5K ﹤0.01% 7314

Other funds holding ENSC

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TIAM2
Tru Independence Asset Management 2 Portland, Oregon $163M AUM 18.06% 1-Year Est. Return

Morgan Stanley's ENSC Position: Q3 2025 in Review

Morgan Stanley sold out of Ensysce Biosciences (ENSC) in Q3 2025, closing a stake of 378 shares — an estimated $843 sold.

Morgan Stanley first reported a position in ENSC in Q3 2021 and held it in 4 quarters. The position peaked at $10K in Q3 2021. 17 funds tracked by Wall St. Rank hold ENSC as of Q3 2025.

  • Morgan Stanley reported no remaining Ensysce Biosciences position as of Q3 2025 after selling out during the quarter.
  • Morgan Stanley sold 378 Ensysce Biosciences shares in Q3 2025, an estimated $843.
  • Morgan Stanley first reported a position in Ensysce Biosciences in Q3 2021 and held it in 4 quarters.
  • Morgan Stanley's Ensysce Biosciences position peaked at $10K in Q3 2021.
  • 17 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q3 2025.

Based on Morgan Stanley's 13F filing for Q3 2025, filed 14 Nov 2025.